Medicine and Dentistry
Visual Impairment
100%
Giant-Cell Arteritis
85%
Optic Nerve
71%
Disease
59%
Optic Neuropathy
56%
Papilledema
54%
Visual Acuity
44%
Arteritic Anterior Ischemic Optic Neuropathy
42%
Magnetic Resonance Imaging
41%
Age Related Macular Degeneration
40%
Headache
39%
Diplopia
36%
Optic Neuritis
34%
Idiopathic Intracranial Hypertension
34%
Agents Acting on the Eye
31%
Eye Pain
29%
Optical Coherence Tomography
29%
Ptosis
27%
Visual Field
27%
Retinopathy
26%
Clinician
22%
Diagnosis
21%
Retinal Nerve Fiber Layer
21%
Vision
21%
Edema
21%
C Reactive Protein
20%
Temporal Artery
19%
Leber Hereditary Optic Neuropathy
19%
Eye Disease
19%
Optic Nerve Atrophy
19%
Surgery
19%
Neurologic Disease
18%
Fluorescein Angiography
17%
Geographic Atrophy
17%
Intraocular Pressure
17%
Biopsy Technique
17%
Prevalence
16%
Clostridium Botulinum Type A
16%
Neoplasm
16%
Cerebrospinal Fluid
16%
Intracranial Hypertension
16%
Ophthalmoparesis
15%
Myasthenia gravis
15%
Best Corrected Visual Acuity
15%
Maculopathy
15%
Upper Eyelid
14%
Contact Lens
14%
Strabismus
14%
Injury
14%
Erythrocyte Sedimentation Rate
14%
Keyphrases
Giant Cell Arteritis
86%
Vision Loss
80%
Optic Neuritis
53%
Optic Neuropathy
51%
Optic Nerve
49%
Papilledema
48%
Idiopathic Intracranial Hypertension
42%
Older Women
39%
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
39%
Age-related Macular Degeneration
35%
Visual Acuity
34%
Older Men
34%
Benign Essential Blepharospasm
33%
Eye Pain
31%
Left Eye
30%
Right Eye
30%
Botulinum Neurotoxin (BoNT)
30%
Myasthenia Gravis
28%
Treatment Trials
27%
Neuro-ophthalmology
27%
Headache
27%
Visual Field
26%
Confidence Interval
25%
Thyroid Eye Disease
25%
Retinal Nerve Fiber Layer Thickness (RNFLT)
24%
Clinical Characteristics
23%
Magnetic Resonance Imaging
23%
Visual Field Defect
20%
Leber Hereditary Optic Neuropathy
19%
Visual Outcome
18%
Fluorescein Angiography
18%
Optic Atrophy
18%
Diplopia
17%
Botulinum Toxin Injection
17%
Extraocular muscles
17%
Spectral Domain Optical Coherence Tomography (SD-OCT)
16%
Etiology
16%
C-reactive Protein
16%
Ocular Manifestations
16%
Intraocular Pressure
16%
Best-corrected Visual Acuity
15%
Risk Factors
15%
Periocular
15%
United States
15%
Increased Intracranial Pressure
14%
Central Nervous System
14%
Geographic Atrophy
14%
Neuroimaging
14%
Phase II Trial
14%
Ocular Trauma
14%